Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : JSI-1187,Dabrafenib Mesylate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : JSI-1187 is a selective and orally administered small molecule inhibitor of ERK1 and ERK2. In preclinical studies, JSI-1187 demonstrated high potency against a variety of tumors with MAPK pathway mutations.
Product Name : JSI-1187
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 01, 2023
Lead Product(s) : JSI-1187,Dabrafenib Mesylate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
JS InnoPharm Announces First Patient Dosed with JSI-1187
Details : The study is being conducted at 4 NCI-designated Comprehensive Cancer Centers in the U.S. JS InnoPharm holds the U.S. IND for JSI-1187, and this trial is being managed by Strategia Pharmaceuticals LLC, JS InnoPharm’s clinical development partner in the...
Product Name : JSI-1187
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 07, 2020
Reset All
